In this episode, Brad and Denali dive into recent industry developments, including Bay Pine's $1.5 billion acquisition of CenExel clinical research site network, the FDA's potential shift to AI-based animal testing alternatives, growing challenges with clinical trial recruitment and public trust, emerging pharmaceutical import tariffs, and the ongoing wave of layoffs in the life sciences sector. The discussion offers candid insights into the evolving landscape of clinical research, technology, and market dynamics.